Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial

医学 彭布罗利珠单抗 打开标签 前列腺癌 肿瘤科 内科学 临床试验 癌症 免疫疗法
作者
Rahul Aggarwal,Stephanie Starzinski,Ivan de Kouchkovsky,Vadim S. Koshkin,Rohit Bose,Jonathan Chou,Arpita Desai,Daniel H. Kwon,Samuel Kaushal,Lauren Trihy,Medini Rastogi,Robin Ippisch,Maya Aslam,Terence W. Friedlander,Felix Y. Feng,David Y. Oh,Alexander Cheung,Eric J. Small,Michael J. Evans,Lawrence Fong
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:24 (11): 1266-1276 被引量:68
标识
DOI:10.1016/s1470-2045(23)00451-5
摘要

Summary

Background

Checkpoint inhibitors have been shown to have limited activity in patients with metastatic castration-resistant prostate cancer. We aimed to determine whether a single dose of lutetium-177 [177Lu]-prostate-specific membrane antigen (PSMA)-617 (177Lu-PSMA-617) followed by maintenance pembrolizumab was safe and could induce durable clinical benefit.

Methods

We did an open-label, dose-expansion, phase 1 study at the University of California, San Francisco (San Fransisco, CA, USA). Eligible patients were men aged 18 years or older with progressive metastatic castration-resistant prostate cancer who had an Eastern Cooperative Oncology Group performance status of 0 or 1, had progression on one or more androgen signalling inhibitors, and at least three PSMA-avid lesions on 68Ga-PSMA-11 positron emission tomography. In part A, patients were enrolled sequentially to one of three schedules in which a single dose of 177Lu-PSMA-617 (7·4 GBq) was given intravenously 28 days before (schedule 1), concomitant with (schedule 2), or 21 days after (schedule 3) the start of maintenance intravenous pembrolizumab (200 mg every 3 weeks). In part B, 25 patients were enrolled using the recommended phase 2 schedule. The primary endpoint in part A was determination of the recommended phase 2 schedule, and in part B, the objective response rate. The analysis set included all patients who received at least one dose of pembrolizumab or 177Lu-PSMA-617. This study is registered with ClinicalTrials.gov, NCT03805594.

Findings

Between Aug 8, 2019 and May 7, 2022, 43 male patients were enrolled (n=18 part A [six patients per schedule]; n=25 part B), with a median follow-up of 16·5 months (IQR 12·2–21·9). Schedule 1 was selected as the recommended phase 2 schedule for part B, on the basis of safety and feasibility of administration observed in part A. In part B, 14 (56%; 95% CI 35–76) of 25 patients had a confirmed objective response. Two (5%) of 43 patients had a treatment-related adverse event of grade 3 or worse (grade 3 arthritis in schedule 2, grade 3 pneumonitis in schedule 3). One serious adverse event (one death due to aspiration pneumonia) and no treatment-related deaths were observed.

Interpretation

A single priming dose of 177Lu-PSMA-617 followed by pembrolizumab maintenance was safe and had encouraging preliminary activity in patients with metastatic castration-resistant prostate cancer.

Funding

Prostate Cancer Foundation, National Cancer Institute, Novartis Pharmaceuticals, and Merck.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小小阳完成签到 ,获得积分10
刚刚
丘比特的应助被飞翔868采纳,获得10
刚刚
刚刚
上好佳完成签到,获得积分10
1秒前
大个的应助被平安喜樂采纳,获得10
1秒前
1秒前
HHW完成签到,获得积分10
1秒前
灵巧尔蓝发布了新的文献求助10
1秒前
weiquanfei完成签到,获得积分20
2秒前
国色天香发布了新的文献求助10
2秒前
2秒前
2秒前
实验室的应助被CarryLJR采纳,获得30
2秒前
小小完成签到,获得积分10
2秒前
顺心夜南发布了新的文献求助10
3秒前
Cc1发布了新的文献求助10
3秒前
3秒前
zhang-gentle发布了新的文献求助10
3秒前
太胖了你完成签到,获得积分10
3秒前
NexusExplorer的应助被故事的角色采纳,获得10
4秒前
马婷完成签到 ,获得积分10
4秒前
4秒前
4秒前
Tyh完成签到 ,获得积分10
4秒前
饺子完成签到,获得积分10
4秒前
哈哈哈完成签到,获得积分10
4秒前
顾矜的应助被Code_king采纳,获得10
4秒前
传奇3的应助被Code_king采纳,获得10
4秒前
小小发布了新的文献求助10
4秒前
5秒前
斯文败类的应助被Code_king采纳,获得10
5秒前
小蘑菇的应助被Code_king采纳,获得10
5秒前
科研通AI6.4的应助被LIXI采纳,获得10
5秒前
小二郎的应助被Code_king采纳,获得10
5秒前
CipherSage的应助被Code_king采纳,获得10
5秒前
weiquanfei发布了新的文献求助20
5秒前
酷波er的应助被Code_king采纳,获得10
5秒前
annzl完成签到,获得积分10
5秒前
科目三的应助被Code_king采纳,获得10
6秒前
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176748
求助须知:如何正确求助?哪些是违规求助? 9567993
关于积分的说明 21796041
捐赠科研通 7771502
什么是DOI,文献DOI怎么找? 3432161
关于科研通互助平台的介绍 2556472
邀请新用户注册赠送积分活动 2477761